References
- Casteli WP. Epidemiology of coronary heart disease: the Framingham study. Am J Med 1984; 76: 4–12.
- Martin MJ, Hulley SB, Browner WS. Serum cholesterol, blood pressure and mortality: implications from a cohort of 361, 662 men. Lancet 1986; ii: 933–6.
- Forbes J Alison. Are HMG-CoA reductase inhibitors cost-effective?. Drug and Therapy Perspective 1997; 9(9): 1–6
- Van der Weijden T, Knottnerus JA, Ament AJHA, Stoffers HEJH, Grol RPTM. Economic evaluation of cholesterol related interventions in general practice. An appraisal of the evidence. J Epid Comm Health 1998; 52: 586–94.
- Muldoon MF, Criqui MH. The emerging role of statins in the prevention of coronary heart disease. BMJ Editorials 1997; 315: 1554–5.
- Garber A, Gotto AM, White H, van Boven J. Hyperlipidaemia: when should treatment be initiated?. Drug and Therapy perspective 1997; 9(9): 7–13
- Betteridge J. The management of Dyslipidaemia. Let them eat cake?. Odyssey 1996; 2(1): 40–7.
- Byrne CD, Wild S. Lipids and secondary prevention of ischaemic heart disease. BMJ editorials 1996; 313: 1273–4.
- Raal FJ. Cholesterol—the pivotal risk factor for artherosclerosis. Specialist Focus Journal—Cardiology 1996; Sept: 8–10.
- Ealing, Hammersmith and Hounslow Health Authority. Dyslipidaemia. Drug and Therapeutics Advisory Group 1996; Nov: 1–12.
- Smith SC. Lessons from cholesterol-lowering trials. Am Jour Med 1998; 104: 28–31.
- Rosengren A. Cholesterol: how low is low enough? BMJ 1998: 317: 425–6
- Van Velden DP. The Cholesterol Controversy. South African Family Practice 2001; 23(5): 12–5.
- Crowther NJ, Paiker JE. Familial hypercholesterolemia: A South African perspective. SA Fam Pract 2003; 45(3): 43–7.
- Mash B, editor. Handbook of Family Medicine. Southern Africa: Oxford; 2000.
- McWhinney I. A Textbook of Family Practice. New York: Oxford University Press; 1989.